graduation at Molecular Cellular And Develomental Biology from University of Colorado (1987) and doctorate at Immunology And Microbiology from University Of Colorado Medical Center (1992). Has experience in Immunology, focusing on Celular Imunology, acting on the following subjects: leishmaniasis, citocinas, cytokines, citocina and imunoregulacao. (Source: Lattes Curriculum)
| Articles published in Pesquisa para Inovação FAPESP about the researcher: |
| FAPESP launches Engineering Research Centers with Embraer, Ericsson and GSK |
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Immune based therapeutics such as checkpoint inhibitors have proven to work across several cancer types and the potential impact novel immuno-oncology targets can have on inducing anti-cancer responses, either as standalone, or as combination/adjuvant therapies is great. Thus, our central overriding scientific focus is to discover and validate immunoregulatory targets with the potential t…
The overall response rate (ORR) in patients treated with immune checkpoints varies greatly and ranges from 30% (Head and Neck cancer) to as high as 60% as a first line therapy in malignant melanoma. Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibition therapy is up to 45% as first line therapy. The elucidation of the factors responsible for treatment failure is f…
Triple negative breast cancer (TNBC) is an aggressive neoplasm characterized by the non-expression of estrogen receptor and progesterone as well as the lack of expression of the HER2 gene. Currently, treatment is based on chemotherapy followed by surgery, where 50% of patients achieve complete recovery, while in the group of patients who do not respond, is noted a tumor progression with a…
The present proposal refers to the communication strategy for the Immuno-Oncology Research Center Project (CRIO) and the dissemination plan from the beginning of the project, which includes dissemination of the center's research to priority target groups through extensive journalistic dissemination in the main social media and means of communication. Tools for the communication strategy w…
(Only some records are available in English at this moment)
Head and neck tumors still show a high incidence in Brazil and in the world, with a mortality rate varying between 40 to 50%. Human papillomavirus (HPV) infection is a major risk factor for oropharyngeal squamous cell carcinoma (or epidermoid carcinoma). Some types of high-risk HPV are responsible for the development of neoplastic lesions. In addition, patients with oropharyngeal epidermo…
Immunotherapy has received great attention in the last few years due to its promising results in the control of aggressive tumors and refractory to conventional treatments. Although some patients show good response, the failure treatment rate is still elevated. In addition, the development rate of immune-mediated adverse events is also high. These events compromise the patient's life qual…
The overall rate in patients treated with anti-PD1 therapy is up to 45% as first line therapy in patients with non-small cell lung cancer (NSCLC). In patients with malignant melanoma, the efficacy is around 30%. The elucidation of the factors responsible for treatment failure is fundamental for the development of new therapeutic approaches. Two factors are essential for influencing the pa…
| 2 / 2 | Ongoing research grants |
| 7 / 7 | Ongoing scholarships in Brazil |
| 3 / 3 | Completed scholarships in Brazil |
| 12 / 12 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID